International Clinical Trial: A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Geneva, June 16 -- International Clinical Trials Registry received information related to the study (NCT07001475) titled 'A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder' on June 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Boehringer Ingelheim

Condition: Borderline Personality Disorder Attention Deficit Hyperactivity Disorder

Intervention: Drug: BI 3031185

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 16, 2025

Targ...